1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.

ABSTRACT: The purpose of this study is to determinate progression free survival after 9 months of treatment.

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms,Adenocarcinoma Colorrectal Metastásico.

PROVIDER: 2030383 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR